Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001927065 | SCV002202905 | uncertain significance | Acrocallosal syndrome | 2024-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 290 of the KIF7 protein (p.Gly290Glu). This variant is present in population databases (rs531693490, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with KIF7-related conditions. ClinVar contains an entry for this variant (Variation ID: 1425997). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on KIF7 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004988938 | SCV005611577 | uncertain significance | Inborn genetic diseases | 2024-07-26 | criteria provided, single submitter | clinical testing | The c.869G>A (p.G290E) alteration is located in exon 4 (coding exon 3) of the KIF7 gene. This alteration results from a G to A substitution at nucleotide position 869, causing the glycine (G) at amino acid position 290 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005006248 | SCV005640349 | uncertain significance | Acrocallosal syndrome; Multiple epiphyseal dysplasia, Al-Gazali type; Hydrolethalus syndrome 2 | 2024-04-22 | criteria provided, single submitter | clinical testing |